SEC Tracker
Get the app

Vogenx VOGX

Vogenx Q2 FY26: net loss $384K; diluted EPS −$0.07

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Vogenx reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$384KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.07No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$193KNo year-earlier figure tagged10-Q balance sheet, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Vogenx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX